This is a story about three PD1×CTLA4 bispecific antibodies, with three engineering philosophies, three very different safety stories, and important development lessons hiding in the details…

In our latest analysis we asked a provocative question:

What can lorigerlimab, volrustomig, and cadonilimab tell us about the design choices shaping antibody development?

To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers